Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentric Randomized Phase I/IIa Trial of the Safety and Immunogenicity of a Therapeutic Anti-HPV DC Targeting Vaccine in Patients With Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer

NCT06007092 is registered in ClinicalTrials.gov with Gustave Roussy, Cancer Campus, Grand Paris as lead sponsor.

NCT NCT06007092
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06007092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentric Randomized Phase I/IIa Trial of the Safety and Immunogenicity of a Therapeutic Anti-HPV DC Targeting Vaccine in Patients With Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer
Lead sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2023
Completion date
March 27, 2026
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult disease, head and neck carcinoma